Skip to content
LATEST
Health

HHS Suspends Enforcement Against Compounding Pharmacies for Six Unapproved Peptides

HHS has authorized compounding pharmacies to distribute six unapproved peptides, bypassing standard FDA safety review processes to address gray market…

HHS Suspends Enforcement Against Compounding Pharmacies for Six Unapproved Peptides

The Department of Health and Human Services (HHS) has announced a policy of enforcement discretion regarding six unapproved peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. Compounding pharmacies may now produce and distribute these substances without facing legal action, despite their current lack of FDA approval. This directive bypasses the standard regulatory process, which typically requires formal rule-making and public comment periods before adding ingredients to the bulk drug substances list.

Officials stated the move aims to mitigate risks associated with the unregulated "gray market" for these compounds. While the FDA has previously concluded that insufficient data exists to verify the safety or efficacy of these peptides, the new policy mandates that pharmacies certify product purity and report adverse events.

Critics argue this shift undermines established safety protocols and regulatory oversight. The decision follows the appointment of several individuals with industry ties to an FDA advisory panel, raising concerns regarding the influence of external stakeholders on public health governance and drug safety standards.

More stories

Latest news